同步辅助放化疗改善子宫浆液性癌无病生存
该回顾性研究纳入162例FIGO I-IVA期子宫浆液性癌患者,分析不同辅助治疗模式的结局。远处转移是最常见失败模式(5年37%)。在I-II期患者中,化疗(单用或联合放疗)及联合放化疗的无病生存显著优于其他治疗。毒性以轻度为主,无4-5级事件。
要点
- 远处转移是子宫浆液性癌各期最常见复发模式,5年达37%。
- I-II期患者中,联合放化疗较单一辅助治疗或未治疗显著改善无病生存。
- 辅助治疗毒性轻微,仅少量3级事件,无4-5级事件。
核心结论
- 子宫浆液性癌复发率和死亡率高,远处转移是各期最常见失败模式。
- 早期(I-II期)患者接受联合放化疗较单一辅助治疗或未治疗可改善5年无病生存。
研究设计与样本
- 单中心回顾性研究,纳入162例FIGO I-IVA期子宫浆液性癌患者。
- 记录基线特征、治疗细节、临床结局和毒性数据,中位随访3.4年(范围0.3-26年)。
主要发现
- 辅助治疗分布:14%未接受辅助治疗,28%单纯放疗,15%单纯化疗,43%联合放化疗。
- 5年远处转移率为37%,为最常见复发类型。
- I-IVA期总体人群中,不同治疗类型结局无显著差异。
- 毒性结局良好,3级事件极少,无4级或5级事件。
临床怎么用
- 对于早期(I-II期)子宫浆液性癌,可考虑联合放化疗作为辅助治疗策略以改善无病生存。
- 鉴于远处转移高发,辅助治疗决策需关注全身控制。
局限性
- 回顾性单中心设计,存在选择偏倚可能。
- 中位随访3.4年,部分患者随访时间较短。
- 原文未报告各亚组的具体样本量及多因素校正结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Uterine serous carcinoma (USC) is a rare but aggressive endometrial cancer histology. We reviewed outcomes for patients with USC to identify the best adjuvant treatment strategy. METHODS AND MATERIALS: We retrospectively identified 162 patients with The International Federation of Gynecology and Obstetrics (FIGO) stage I-IVA USC treated at our institution. Baseline characteristics, treatment details, clinical outcomes, and toxicity data were recorded. RESULTS: Median follow-up was 3.4 years (0.3-26 years). A variety of adjuvant therapy strategies were employed: 14% no adjuvant therapy, 28% radiation alone, 15% chemotherapy alone, and 43% combined chemotherapy and radiation. Distant metastasis was the most common type of recurrence (37% at 5 years). For patients with stage I-IVA disease, there were no significant differences in outcomes by treatment type. For patients with stage I-II disease (70% of the cohort), disease-free survival was significantly higher after chemotherapy (alone or with radiation therapy, P = .005) and after combined chemotherapy and radiation compared with all other treatments (P = .025). Toxicity outcomes were favorable, with minimal grade 3 and no grade 4 or 5 events. CONCLUSIONS: Patients with USC experience high rates of recurrence and mortality. Distant metastasis is the most common pattern of failure for all stages. For patients with early-stage disease, combined chemotherapy and radiation improves 5-year disease-free survival compared with either single adjuvant treatment alone or no adjuvant treatment. The relatively large group of patients with USC included in this study may account for our ability to detect this improvement whereas clinical trials have failed to do so, possibly owing to the relatively small percentages of patients with USC enrolled.
引用
- Arden JD, Marvin K, Ye H, et al. Combined Adjuvant Chemotherapy and Radiation Therapy Improves Disease-Free Survival for Uterine Serous Cancer. Adv Radiat Oncol. 2020. PMID: 33305084. doi:10.1016/j.adro.2020.08.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。